Correction to: Iron and infection (Int J Hematol, 10.1007/s12185-017-2366-2);Iron and infection

International Journal of Hematology

Volumn 107, Issue 1, 2018, Pages 7-15

  Ganz, Tomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ferroportin; Hepcidin; Lactoferrin; Lipocalin; Nramp2

Indexed keywords

HEPCIDIN; IRON; LACTOFERRIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFERRIN; AUTACOID; CATION TRANSPORT PROTEIN; CYTOKINE; LACTOFERRICIN B; LIPOCALIN; METAL TRANSPORTING PROTEIN 1; SOLUTE CARRIER FAMILY 11- (PROTON-COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2;

ANEMIA; ARTICLE; BACTERIUM; BETA THALASSEMIA; ERYTHROCYTE LIFESPAN; EXTRACELLULAR FLUID; HEMOCHROMATOSIS; HUMAN; INFECTION; INFLAMMATION; IRON HOMEOSTASIS; IRON OVERLOAD; IRON RESTRICTION; MACROPHAGE; NONHUMAN; PHAGOCYTE; SIDEROPHILIC BACTERIA; SURFACE PROPERTY; TRANSFERRIN BLOOD LEVEL; ANIMAL; DEFICIENCY; DISEASE PREDISPOSITION; IMMUNOLOGY; LEUKOCYTE; MACROPHAGE ACTIVATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CATION TRANSPORT PROTEINS; CYTOKINES; DISEASE SUSCEPTIBILITY; HEPCIDINS; HUMANS; INFECTION; INFLAMMATION MEDIATORS; IRON; IRON OVERLOAD; LACTOFERRIN; LEUKOCYTES; LIPOCALINS; MACROPHAGE ACTIVATION; MACROPHAGES; TRANSFERRIN;

EID: 85034240637     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-017-2385-z     Document Type: Erratum

References (55)

1. Archibald F. Lactobacillus plantarum, an organism not requiring iron. FEMS Microbiol Lett. 1983;19:29–32.
2. Huber C, Wächtershäuser G. Activated acetic acid by carbon fixation on (Fe, Ni)S under primordial conditions. Science. 1997;276:245–7.
3. Camprubi E, Jordan SF, Vasiliadou R, et al. Iron catalysis at the origin of life. IUBMB Life. 2017;69:373–81.
4. Ilbert M, Bonnefoy V. Insight into the evolution of the iron oxidation pathways. Biochim Biophys Acta (BBA) Bioenerg. 2013;1827:161–75.
5. Barber MF, Elde NC. Buried treasure: evolutionary perspectives on microbial iron piracy. Trends Genet. 2015;31:627–36.
6. Mayeur S, Spahis S, Pouliot Y, et al. Lactoferrin, a pleiotropic protein in health and disease. Antioxid Redox Signal. 2016;24:813–36.
7. de Oliveira SC, Bellanger A, Ménard O, et al. Impact of human milk pasteurization on gastric digestion in preterm infants: a randomized controlled trial. Am J Clin Nutr. 2017;105:379–90.
8. Mastromarino P, Capobianco D, Campagna G, et al. Correlation between lactoferrin and beneficial microbiota in breast milk and infant’s feces. Biometals. 2014;27:1077–86.
9. Ward PP, Mendoza-Meneses M, Park PW, et al. Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol. 2008;172:1019–29.
10. Sia AK, Allred BE, Raymond KN. Siderocalins: siderophore binding proteins evolved for primary pathogen host defense. Curr Opin Chem Biol. 2013;17:150–7.
11. Shields-Cutler RR, Crowley JR, Miller CD, et al. Human metabolome-derived cofactors are required for the antibacterial activity of siderocalin in urine. J Biol Chem. 2016;291:25901–10.
12. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917–21.
13. Wu H, Santoni-Rugiu E, Ralfkiaer E, et al. Lipocalin 2 is protective against E. coli pneumonia. Respir Res. 2010;11:96.
14. Cramer EP, Dahl SL, Rozell B, et al. Lipocalin-2 from both myeloid cells and the epithelium combats Klebsiella pneumoniae lung infection in mice. Blood. 2017;129:2813–7.
15. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037–44.
16. Kim A, Fung E, Parikh SG, et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood. 2014;123:1129–36.
17. Gardenghi S, Renaud TM, Meloni A, et al. Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. Blood. 2014;123:1137–45.
18. Deschemin JC, Vaulont S. Role of hepcidin in the setting of hypoferremia during acute inflammation. PLoS One. 2013;8:e61050.
19. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–6.
20. Pietrangelo A, Dierssen U, Valli L, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology. 2007;132:294–300.
21. Verga Falzacappa MV, Vujic SM, Kessler R, et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109:353–8.
22. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–9.
23. Verga Falzacappa MV, Casanovas G, Hentze MW, et al. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med. 2008;86:531–40.
24. Rodriguez R, Jung CL, Gabayan V, et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun. 2014;82:745–52.
25. Guida C, Altamura S, Klein FA, et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood. 2015;125:2265–75.
26. Siddique A, Kowdley KV. Review article: the iron overload syndromes. Aliment Pharmacol Ther. 2012;35:876–93.
27. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393–408 (408 e391–e392).
28. Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51:845–52.
29. Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007;13:97–104.
30. de Feo TM, Fargion S, Duca L, et al. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res. 2001;25:1494–9.
31. Oliver JD. Vibrio vulnificus: death on the half shell. A personal journey with the pathogen and its ecology. Microb Ecol. 2013;65:793–9.
32. Barton JC, Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol. 2009;43:890–3.
33. Kuo C-H, Dai Z-K, Wu J-R, et al. Septic arthritis as the initial manifestation of fatal Vibrio vulnificus septicemia in a patient with thalassemia and iron overload. Pediatr Blood Cancer. 2009;53:1156–8.
34. Bergmann TK, Vinding K, Hey H. Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis. Scand J Gastroenterol. 2001;36:891–5.
35. Hopfner M, Nitsche R, Rohr A, et al. Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis. Scand J Gastroenterol. 2001;36:220–4.
36. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis. 2006;6:226–33.
37. Arezes J, Jung G, Gabayan V, et al. Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell Host Microbe. 2015;17:47–57.
38. Stefanova D, Raychev A, Arezes J, et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood. 2017;. https://doi.org/10.1182/blood-2017-03-772715.
39. Michels KR, Zhang Z, Bettina AM, et al. Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. JCI Insight. 2017;2:e92002.
40. Libregts SF, Gutierrez L, de Bruin AM, et al. Chronic IFN-gamma production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood. 2011;118:2578–88.
41. Allen DA, Breen C, Yaqoob MM, et al. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med. 1999;47:204–11.
42. Arezes J, Nemeth E. Hepcidin and iron disorders: new biology and clinical approaches. Int J Lab Hematol. 2015;37(Suppl 1):92–8.
43. Forbes JR, Gros P. Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interactions. Trends Microbiol. 2001;9:397–403.
44. North RJ, LaCourse R, Ryan L, et al. Consequence of Nramp1 deletion to mycobacterium tuberculosis infection in mice. Infect Immun. 1999;67:5811–4.
45. Yuan L, Ke Z, Guo Y, et al. NRAMP1 D543N and INT4 polymorphisms in susceptibility to pulmonary tuberculosis: a meta-analysis. Infect Genet Evol. 2017;54:91–7.
46. Wessling-Resnick M. Nramp1 and other transporters involved in metal withholding during infection. J Biol Chem. 2015;290:18984–90.
47. Soe-Lin S, Apte SS, Mikhael MR, et al. Both Nramp1 and DMT1 are necessary for efficient macrophage iron recycling. Exp Hematol. 2010;38:609–17.
48. Neves JV, Wilson JM, Kuhl H, et al. Natural history of SLC11 genes in vertebrates: tales from the fish world. BMC Evol Biol. 2011;11:106.
49. Nix RN, Altschuler SE, Henson PM, et al. Hemophagocytic macrophages harbor Salmonella enterica during persistent infection. PLoS Pathog. 2007;3:e193.
50. Chlosta S, Fishman DS, Harrington L, et al. The iron efflux protein ferroportin regulates the intracellular growth of Salmonella enterica. Infect Immun. 2006;74:3065–7.
51. Willemetz A, Beatty S, Richer E, et al. Iron- and hepcidin-independent downregulation of the iron exporter ferroportin in macrophages during salmonella infection. Front Immunol. 2017;8:498.
52. Cartwright GE, Lee GR. The anaemia of chronic disorders. Br J Haematol. 1971;21:147–52.
53. Bullock GC, Delehanty LL, Talbot AL, et al. Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood. 2010;116:97–108.
54. Hayden SJ, Albert TJ, Watkins TR, et al. Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med. 2012;185:1049–57.
55. Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995;13:32–7.